EULAR 2021: 10% Intravenous Immunoglobulin Effective in Dermatomyositis
Results of ProDERM trial led to regulatory approval in Europe
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Results of ProDERM trial led to regulatory approval in Europe
Only registered members have full access to PracticeUpdate content.